EGFR and non-small cell lung carcinoma: The proportion of epidermal growth factor receptor (EGFR) mutations is much higher in patients with non-squamous NSCLC in Asia (40–55%) than in the US and Europe (10–15%), while Kirsten rat sarcoma viral oncogene homolog (KRAS) mutations are less common in Asian patients (8–10%) than in Western patients (20–30%) [5,6].